Blog
Get the latest perspectives on real world data and evidence.
Targeted Epidemiology in RWE: Purpose and Patients with Rare Disease
Study Purpose and Population Epidemiology of rare diseases is important for clinicians to consider, as prevalence and incidence inform the healthcare community about likelihood of disease within an at-risk population. Studies in epidemiology also help to support...
2022 Winter Newsletter
With access to more than 80% of the US healthcare system, we use patient-level data across all-provider types to support evidence generation needs.
read moreHow to Maximize Access Planning: From Covered Lives to Clinically Eligible
Clinically eligible lives data powered by STATinMED RWD Insights offer accurate and timely TRUE market opportunity, where detailed utilization management policies are managed, and contracts are negotiated.
read moreLearning the True Burden of Disease Through Real-World Data
Real-world data (RWD) and real-world evidence (RWE) are transforming the future of healthcare, including how Health Economics & Outcomes Research (HEOR) reveals the true burden of disease.
read moreSTATinMED Research Fall Newsletter 2021
With access to more than 80% of the US healthcare system, we use patient-level data across all-provider types to support evidence generation needs.
read moreRare Diseases: Not So Rare Within Real-World Data
Rare diseases are not so rare in RWD. Accounting for variability in access to care based on payer and healthcare infrastructure, our claims data population in STATinMED RWD Insights can help to monitor the outcomes for those with rare diseases and identify gaps in available therapeutics and healthcare resources.
read moreSocial Determinants of Health: What We See in RWE
Through real-world evidence (RWE), prescriptions reveal the process and delivery of healthcare. A prescription for a diagnostic test or medication reflects medical practice patterns, healthcare systems, and payer reimbursement for services.
read moreHow to Maximize RWD Insights in Precision Medicine for Patients with Cancer
With STATinMED RWD Insights we have the power to examine more than 80% of the US healthcare system’s all-payer medical and pharmacy claims, with patient-level data across all-provider types to support a variety of evidence generation needs.
read moreSTATinMED Research News Quarterly – Summer 2021
STATinMED Research is pleased to share the latest updates in our summer newsletter, as we celebrate our new brand and company website.
read more